Kayvan R. Niazi Ph.D.

niaziAdjunct Assistant Professor

Department of Bioengineering

4516 CNSI
310-983-1044 | 310-206-2921fax


  • B.S., University of California, Davis, 1992
  • Ph.D., University of California, Los Angeles, 2000
  • Postdoctoral Research Fellow, University of California, Los Angeles, 2002

Research Interests

My interests lay in the application of early-stage technological breakthroughs in the life sciences towards the development of improved medical therapeutics and devices.  Prior to our employment at Abraxis and our subsequent arrival at UCLA, my colleague Dr. Shahrooz Rabizadeh and I created and co-directed a translational unit at the non-profit Buck Institute for Age Research.  Our group was dedicated to using multidisciplinary research to bridge the “gap” between academic discoveries and industrial commercialization.  Indeed, the majority of my personal research over the past nine years has depended heavily on input and methodologies borrowed from a spectrum of disciplines including cell biology, molecular biology, biochemistry, biophysics, immunology, toxicology, and medicine to bring to bear the fruits of nanotechnology in drug discovery with special emphasis on the modulation of the immune response.  Thus, I look forward to the challenges of identifying and addressing the key issues which currently serve as roadblocks for early medically-relevant technologies at UCLA and eagerly anticipate future successes founded on the current synergy between the creativity and expertise of the faculty and the collective academic and industrial experiences and knowledge that Shahrooz and I possess.


Research Papers

  1. Poksay K., Madden D., Peter A., Niazi K., Banwait S., Crippen D., Bredesen D., Rao R., “Vaolosin-Containing Protein Gene Mutations: Cellular Phenotypes Relevant to Neurodegeneration,” Journal of Molecular Neuroscience. 2011 Jun;44(2):91-102.
  2. Niazi K.R., Ochoa M.T., Sieiling P.A., et al, “Activation of human CD4(+) T cells by targeting MHC class II epitopes to endosomal compartments using human CD1 tail sequences,” Immunology. 2007 Dec;122(4):522-531.
  3. Niazi K.R., Porcelli S.A., Modlin R.L., “The CD1b structure: antigen presentation adapts to a high-fat diet.”  Nat Immunol. 2002 Aug;3(8):703-4.
  4. Stenger S., Hanson D.A., Teitelbaum R., Dewan P., Niazi K.R., Froelich C.J., Ganz T., Thoma-Uszynski S., Melian A., Bogdan C., Porcelli S.A., Bloom B.R., Krensky A.M., Modlin R.L., “An antimicrobial activity of cytolytic T cells mediated by granulysin,” Science. 1998 Oct 2;282(5386):121-125.
  5. Ernst W.A., Maher J., Cho S.G., Niazi K.R., Chatterjee D., Moody D.B., Besra G.S., Watanbe Y., Jensen P.E., Procelli S.A., Kronenberg M., Modlin R.L., “Molecular interaction of CD1b with lipoglycan antigens,” Immunity. 1998 Mar;8(3):331-340.
  6. Jackman R.M., Stenger S., Lee A., Moody D.B., Rogers R.A., Niazi K.R., Sugita M., Modlin R.L., Peters P.J., Porcelli S.A., “The tyrosine-containing cytoplasmic tail of CD1B is essential for its efficient presentation of bacterial lipid antigens,” Immunity. 1998 Mar;8(3):341-351.